Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 9.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 848,235 shares of the biopharmaceutical company’s stock after purchasing an additional 74,063 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Gilead Sciences were worth $71,116,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the business. Kennedy Capital Management LLC acquired a new stake in shares of Gilead Sciences during the 1st quarter worth about $2,946,000. B. Riley Wealth Advisors Inc. raised its holdings in Gilead Sciences by 2.2% during the first quarter. B. Riley Wealth Advisors Inc. now owns 28,519 shares of the biopharmaceutical company’s stock worth $2,137,000 after purchasing an additional 604 shares in the last quarter. Atria Investments Inc lifted its position in shares of Gilead Sciences by 16.2% during the 1st quarter. Atria Investments Inc now owns 89,515 shares of the biopharmaceutical company’s stock worth $6,557,000 after buying an additional 12,507 shares during the last quarter. Cetera Investment Advisers boosted its holdings in shares of Gilead Sciences by 127.6% in the 1st quarter. Cetera Investment Advisers now owns 213,901 shares of the biopharmaceutical company’s stock valued at $15,668,000 after buying an additional 119,909 shares in the last quarter. Finally, Cetera Advisors LLC grew its position in shares of Gilead Sciences by 167.2% in the 1st quarter. Cetera Advisors LLC now owns 82,786 shares of the biopharmaceutical company’s stock valued at $6,064,000 after buying an additional 51,801 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on GILD. Wells Fargo & Company boosted their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Sanford C. Bernstein started coverage on Gilead Sciences in a research note on Thursday, October 17th. They set an “outperform” rating and a $105.00 price target on the stock. Barclays lifted their price target on Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 7th. Mizuho raised their target price on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. Finally, Maxim Group downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Twelve equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $95.41.

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The trade was a 27.31 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the sale, the insider now owns 100,189 shares in the company, valued at $8,398,843.87. This trade represents a 1.96 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 63,735 shares of company stock worth $5,589,030 over the last ninety days. 0.29% of the stock is currently owned by insiders.

Gilead Sciences Price Performance

GILD stock opened at $92.41 on Thursday. The firm has a 50 day moving average of $87.91 and a 200-day moving average of $77.42. The company has a market cap of $115.17 billion, a price-to-earnings ratio of 1,026.78, a PEG ratio of 2.81 and a beta of 0.17. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $98.90.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same period in the previous year, the firm posted $2.29 earnings per share. Gilead Sciences’s revenue was up 7.0% on a year-over-year basis. As a group, equities analysts expect that Gilead Sciences, Inc. will post 4.37 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be issued a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 3.33%. The ex-dividend date of this dividend is Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 3,422.22%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.